LLY
Eli Lilly and Company
- Long-term debt, 2025
- $40.9B
- YoY, 2025
- +43.3%
- 5-year CAGR
- +19.8%
- 10-year CAGR
- +17.8%
Long-term debt
Long-term debt by fiscal year
| Period | Long-term debt | YoY |
|---|---|---|
| 2025 | $40.9B | +43.3% |
| 2024 | $28.5B | +55.7% |
| 2023 | $18.3B | +24.3% |
| 2022 | $14.7B | −4.0% |
| 2021 | $15.3B | −7.5% |
| 2020 | $16.6B | +20.0% |
| 2019 | $13.8B | +50.3% |
| 2018 | $9.2B | −7.5% |
| 2017 | $9.9B | +18.8% |
| 2016 | $8.4B | +5.0% |
| 2015 | $8.0B | +49.5% |
| 2014 | $5.3B | +27.0% |
| 2013 | $4.2B | −23.9% |
| 2012 | $5.5B | +1.0% |
| 2011 | $5.5B | −19.3% |
| 2010 | $6.8B | +2.0% |
| 2009 | $6.6B | +43.7% |
| 2008 | $4.6B | — |